The discovery of beta-adrenergic receptor antagonist propranolol by Sir James Black
in 1964 was a landmark event in the history of cardiovascular therapeutics.[1] It
proved to be the first effective treatment for angina pectoris. Thereafter, the story
of these agents, commonly referred to as beta-blockers, is undoubtedly an unparalleled
one in the era of modern therapeutics. Beta-blockers became the mainstay of treatment
of major cardiovascular diseases (CVDs), including hypertension, angina, myocardial
infarction, and arrhythmias, besides being used for an array of noncardiovascular
indications. The events took a dramatic turn for these versatile agents with the turn
of the century when the landmark MERIT–HF trial, the CIBIS–II trial, and the COPERNICUS
trial paved way for the use of beta-blockers in heart failure – a hitherto absolute
contraindication.[2
3] This particular indication of a selected group of beta-blockers (carvedilol, metoprolol,
bisoprolol, and lately, nebivolol) took the medical world by storm prompting Cruickshank
to observe “beta-blockers continue to surprise us.”[4] The tale of beta-blockers'
utility in clinical conditions where these agents were deemed contraindicated, going
by the rationale of their mechanisms, is no less than an enigma in itself.
Egged upon by such observations, an increasing volume of literature has accumulated
about the utility of beta-blockers in patients of chronic obstructive pulmonary disease
(COPD), despite their potential to exacerbate the condition. Studies suggest that
the use of selective beta-blockers do not result in adverse respiratory effects among
patients with COPD and that selective beta-blockers can be cautiously prescribed for
patients with COPD and CVD.[5
6
7] It is to be noted that most of these patients had concomitant CVD. However, literature
suggests that beta-blockers are underused in such patients as the fear of exacerbating
the condition due to worsening lung function looms large.
The major chunk of evidence on the use of beta-blockers in COPD comes from observational
studies. A recent retrospective cohort study reported 10,638 patients hospitalized
with the diagnosis of acute myocardial infarction (AMI) and received beta-blockers,
of whom 5136 (48.3%) used cardioselective beta-blockers, 5502 (51.7%) used nonselective
beta-blockers, and 95 (0.9%) patients used both selective and nonselective beta-blockers.
The authors concluded that the use of beta-blockers was associated with a lower mortality
rate in patients with COPD after AMI and did not increase the risk of COPD.[8] Some
studies have shown that beta-blockers decrease the risk of acute exacerbation of COPD.
A meta-analysis of 15 retrospective studies involving patients of COPD showed that
beta-blockers use resulted in a significantly lower frequency of exacerbation of COPD
and death as compared to those who did not get these drugs (38% and 28%, respectively).[9]
Another study reported a decrease in exacerbations of COPD in patients on beta-blockers.[10]
However, most data come from patients who had co-existing cardiovascular conditions
for which beta-blockers were indicated, whereas the data on the use of beta-blockers
in patients of COPD without CVD are lacking. Moreover, being observational studies,
the inherent limitations of bias by immeasurable and unrecorded confounding factors
cannot be overlooked.
The proposed mechanisms of the useful effects of beta-blockers in COPD patients come
from animal studies, which reported that administration of beta-blockers increased
the density of pulmonary β2-adrenergic receptors due to their up-regulation. Other
mechanism may include beta-blocker-induced reduction of sympathetic tone, inhibition
of cardiac stimulation by catecholamines, and increased production of nitric oxide
in vascular smooth muscle.[11
12] These agents are also proposed to reduce systemic inflammation and mucus release.
A recent study by Dransfield et al. reported the effects of metoprolol on prevention
of acute exacerbations in patients of COPD in the Beta-blockers for the Prevention
of Acute Exacerbations of COPD Trial.[13] It was a multicenter, prospective randomized,
placebo-controlled trial in which 532 COPD patients without a history of CVD and not
receiving prior beta-blockers were assigned to extended release metoprolol or placebo.
The primary end point was the time until first exacerbation of COPD. However, the
trial was stopped early – due to futility pertaining to primary endpoint and safety
concerns. Metoprolol was associated with a higher risk of exacerbation, leading to
hospitalization (hazard ratio, 1.91; 95% confidence interval, 1.29–2.83) with 11 deaths
reported as compared to five in placebo group. The trial had its own set of limitations
including difficulty in blinding and exclusion of patients on prior beta-blockers.
The authors concluded that the time until first COPD exacerbation was similar in the
two groups, but metoprolol caused more hospitalization due to exacerbation. The results
of this trial indicate cautionary use of beta-blockers for the prevention of exacerbations
in patients of COPD who do not require beta-blockers for any cardiovascular comorbidity.
Till we have more evidence in this context, the basic principle of benefit-to-risk
assessment should be the guiding light while making therapeutic decisions, and till
then, the tale of beta-blockers in the therapeutic arena continues.